Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

NCT01252732 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1019

Enrollment

INDUSTRY

Sponsor class

Conditions

Wound Infection
Abscess
Systemic Inflammation
Cellulitis

Interventions

DRUG: Single-Dose IV Oritavancin Diphosphate
DRUG: IV Vancomycin

Sponsor

Melinta Therapeutics, Inc.